Active, Not Recruiting
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
NCT04014205
- Conditions
- Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
- Locations
-
- Mayo Clinic-Mayo Clinic Hospital-Phoenix Phoenix, Arizona, United States
- Pacific Cancer Medical Center Anaheim, California, United States
- Los Angeles Cancer Network - Good Samaritan Hospital Location Los Angeles, California, United States
- Desert Hematology Oncology Medical Group, Inc. Rancho Mirage, California, United States